CVS HEALTH Corp: Form 10-Q for the period ended Mar 31, 2018
Filed with the SEC on May 2, 2018 and accepted by EDGAR at May 2, 2018, 17:09 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2018-01-01 to 2018-03-31 | $45.69bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2018-01-01 to 2018-03-31 | $38.83bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2018-01-01 to 2018-03-31 | $6.86bn | us-gaap:GrossProfit |
| Operating income | 3 months2018-01-01 to 2018-03-31 | $1.95bn | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2018-01-01 to 2018-03-31 | $472.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2018-01-01 to 2018-03-31 | $998.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-01-01 to 2018-03-31 | $0.98 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2018-01-01 to 2018-03-31 | $0.98 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2018-01-01 to 2018-03-31 | 1,019,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2018-01-01 to 2018-03-31 | $2.35bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2018-01-01 to 2018-03-31 | $482.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2018-01-01 to 2018-03-31 | $508.0m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2018-03-31 | $42.02bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-03-31 | $71.80bn | us-gaap:AssetsCurrent |
| Total assets | At period end2018-03-31 | $135.14bn | us-gaap:Assets |
| Current liabilities | At period end2018-03-31 | $30.25bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-03-31 | $96.46bn | us-gaap:Liabilities |
| Long-term debt | At period end2018-03-31 | $61.55bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2018-03-31 | $3.54bn | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2018-03-31 | $38.67bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-18-003777. Last ingested by Listed: Nov 6, 2026, 17:47 ET. Listed shows no prices and gives no investment advice.